Roswell Park First in Region to Offer Adaptive Radiotherapy for Precision Tumor Treatment - Summary - MDSpire

Roswell Park First in Region to Offer Adaptive Radiotherapy for Precision Tumor Treatment

Roswell Park Comprehensive Cancer Center is proud to be the first care provider in the region to begin offering adaptive radiation therapy

  • April 10, 2026

Share

Objective:

To introduce and explain the benefits of adaptive radiation therapy at Roswell Park Comprehensive Cancer Center.

Approach:
    Key Findings:
    • Roswell Park is the first in the region to offer adaptive radiation therapy.
    • This therapy allows for immediate adjustments to treatment plans, enhancing precision and minimizing side effects.
    • Patients can receive more effective radiation targeting while reducing exposure to surrounding healthy tissues.
    Interpretation:

    Adaptive radiation therapy represents a significant advancement in cancer treatment, allowing for personalized care that adapts to the patient's changing anatomy during treatment.

    Limitations:
    • The availability of adaptive radiation therapy is currently limited to Roswell Park in the region.
    • Implementation may depend on funding and resources from donations.
    Conclusion:

    Adaptive radiation therapy enhances treatment effectiveness and reduces side effects, marking a milestone in cancer care at Roswell Park.

    Sources:

Original Source(s)

Roswell Park First in Region to Offer Adaptive Radiotherapy for Precision Tumor Treatment

  • April 10, 2026

Related Content

Promising early results for a new treatment in head and neck cancer

Victoria Villaflor, MD shared promising early results at ASCO 2026 for a new treatment approach in head and neck cancer.

  • June 24, 2026

  • 1 min
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • by

  • June 24, 2026

  • 4 min
AI Framework Helps Identify New CAR T Target

A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models

  • July 6, 2026

  • 3 min